Figure 5.
Dose–response in early treatment with tetracycline i.p. of body weight and clinical score of C57BL/6J mice after lung infection with C. trachomatis serovar D and early treatment with different dosages of tetracycline i.p. (TetE). Mice were intranasally (i.n.) infected with 8 × 106 IFU (of a new preparation) of C. trachomatis (CtrD) or mock material (Mock) and subsequently monitored until they were euthanized on day 6 p.i. Tetracycline was applied once a day on days 1–3. In this experiment 20 (TetE High), 5 (TetE Medium), and 1.25 (TetE Low) mg kg−1 body weight tetracycline or buffer (NaCl) were used. (A) Body weight is depicted as means ± standard errors of the means. (B) Clinical score values are depicted as medians ± interquartile ranges. Asterisks indicate (for day 4 p.i. as example) significant differences between the infected groups: *P = 0.05; **P = 0.01; ***P = 0.001; n.s. = not significant. On days 3 and 5, and partially also on day 6 p.i., depending on the varying dosages of tetracycline there were also significant differences between the body weights of several CtrD-infected groups (see also Table S1, Supporting Information).

Dose–response in early treatment with tetracycline i.p. of body weight and clinical score of C57BL/6J mice after lung infection with C. trachomatis serovar D and early treatment with different dosages of tetracycline i.p. (TetE). Mice were intranasally (i.n.) infected with 8 × 106 IFU (of a new preparation) of C. trachomatis (CtrD) or mock material (Mock) and subsequently monitored until they were euthanized on day 6 p.i. Tetracycline was applied once a day on days 1–3. In this experiment 20 (TetE High), 5 (TetE Medium), and 1.25 (TetE Low) mg kg−1 body weight tetracycline or buffer (NaCl) were used. (A) Body weight is depicted as means ± standard errors of the means. (B) Clinical score values are depicted as medians ± interquartile ranges. Asterisks indicate (for day 4 p.i. as example) significant differences between the infected groups: *P = 0.05; **P = 0.01; ***P = 0.001; n.s. = not significant. On days 3 and 5, and partially also on day 6 p.i., depending on the varying dosages of tetracycline there were also significant differences between the body weights of several CtrD-infected groups (see also Table S1, Supporting Information).

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close